On the public citation graph

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma

0 signed · 597 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.

Claim with ORCID

Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.

See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1016/j.molcel.2004.12.021openalex-snapshot

Global Impairment of the Ubiquitin-Proteasome System by Nuclear or Cytoplasmic Protein Aggregates Precedes Inclusion Body Formation

inferredcites →https://doi.org/10.1016/s0092-8674(03)00939-5openalex-snapshot

The Deacetylase HDAC6 Regulates Aggresome Formation and Cell Viability in Response to Misfolded Protein Stress

inferredcites →https://doi.org/10.1016/s0962-8924(00)01852-3openalex-snapshot

Aggresomes, inclusion bodies and protein aggregation

inferredcites →https://doi.org/10.1016/s1074-5521(03)00095-4openalex-snapshot

Multidimensional Chemical Genetic Analysis of Diversity-Oriented Synthesis-Derived Deacetylase Inhibitors Using Cell-Based Assays

inferredcites →https://doi.org/10.1016/s1471-4892(03)00084-5openalex-snapshot

Histone deacetylases

inferredcites →https://doi.org/10.1016/s1535-6108(04)00050-9openalex-snapshot

Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors

inferredcites →https://doi.org/10.1021/ja0341440openalex-snapshot

Structural Biasing Elements for In-Cell Histone Deacetylase Paralog Selectivity

inferredcites →https://doi.org/10.1034/j.1600-065x.2003.00053.xopenalex-snapshot

Novel therapeutic approaches for multiple myeloma

inferredcites →https://doi.org/10.1034/j.1600-0854.2002.30602.xopenalex-snapshot

Hassles with Taking Out the Garbage: Aggravating Aggresomes

inferredcites →https://doi.org/10.1038/nrc952openalex-snapshot

Molecular mechanisms of novel therapeutic approaches for multiple myeloma

inferredcites →https://doi.org/10.1038/sj.onc.1204623openalex-snapshot

The role of tumor necrosis factor α in the pathophysiology of human multiple myeloma: therapeutic applications

inferredcites →https://doi.org/10.1038/sj.onc.1207170openalex-snapshot

Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma

inferredcites →https://doi.org/10.1038/sj.onc.1208118openalex-snapshot

p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells

inferredcites →https://doi.org/10.1056/nejm200406173502526openalex-snapshot

Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma

inferredcites →https://doi.org/10.1056/nejmoa030288openalex-snapshot

A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma

inferredcites →https://doi.org/10.1056/nejmoa032290openalex-snapshot

Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma

inferredcites →https://doi.org/10.1073/pnas.0430973100openalex-snapshot

Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation

inferredcites →https://doi.org/10.1073/pnas.202445099openalex-snapshot

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

inferredcites →https://doi.org/10.1074/jbc.m200360200openalex-snapshot

NF-κB as a Therapeutic Target in Multiple Myeloma

inferredcites →https://doi.org/10.1182/blood-2002-06-1768openalex-snapshot

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

inferredcites →https://doi.org/10.1182/blood-2002-08-2543openalex-snapshot

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341

inferredcites →https://doi.org/10.1182/blood-2002-11-3514openalex-snapshot

Molecular sequelae of histone deacetylase inhibition in human malignant B cells

inferredcites →https://doi.org/10.1182/blood-2003-01-0233openalex-snapshot

NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma

inferredcites →https://doi.org/10.1182/blood-2004-05-1760openalex-snapshot

VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis

inferredcites →https://doi.org/10.1182/blood-2004-06-2281openalex-snapshot

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma

inferredcites →https://doi.org/10.1182/blood.v82.12.3712.3712openalex-snapshot

Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion

inferredcites →https://doi.org/10.1200/jco.1992.10.2.334openalex-snapshot

Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials.

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4189784openalex-extracted

The Small Molecular Compound CC1007 Suppresses Multiple Myeloma Via Upregulation of Nur77

inferred← citeshttps://doi.org/10.1002/3527600906.mcb.201100010openalex-snapshot

Epigenetic Medicine

inferred← citeshttps://doi.org/10.1002/9781118592168.ch33openalex-snapshot

Multiple Myeloma

inferred← citeshttps://doi.org/10.1002/9781119000822.hfcm122openalex-snapshot

Plasma Cell Tumors

inferred← citeshttps://doi.org/10.1002/9783527619375.ch9aopenalex-snapshot

Diversity‐oriented Synthesis

inferred← citeshttps://doi.org/10.1002/adma.200602098openalex-snapshot

Gold Nanoparticles Inhibit the Proliferation of Multiple Myeloma Cells

inferred← citeshttps://doi.org/10.1002/adtp.202300421openalex-snapshot

Valproate Mediated Proteasome Dysfunctions Induce Apoptosis

inferred← citeshttps://doi.org/10.1002/ajh.24236openalex-snapshot

Myeloma today: Disease definitions and treatment advances

inferred← citeshttps://doi.org/10.1002/ajh.24402openalex-snapshot

Multiple myeloma: 2016 update on diagnosis, risk‐stratification, and management

inferred← citeshttps://doi.org/10.1002/ajh.25117openalex-snapshot

Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management

inferred← citeshttps://doi.org/10.1002/ajh.25791openalex-snapshot

Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management

inferred← citeshttps://doi.org/10.1002/ange.200703198openalex-snapshot

Fluorous‐Based Small‐Molecule Microarrays for the Discovery of Histone Deacetylase Inhibitors

inferred← citeshttps://doi.org/10.1002/anie.200703198openalex-snapshot

Fluorous‐Based Small‐Molecule Microarrays for the Discovery of Histone Deacetylase Inhibitors

inferred← citeshttps://doi.org/10.1002/bmc.3414openalex-snapshot

Development and validation of a LC‐MS assay for the quantification of ikh12 a novel anti‐tumor candidate in rat plasma and tissues and its application in a pharmacokinetic study

inferred← citeshttps://doi.org/10.1002/cmdc.200800196openalex-snapshot

Pyridylalanine‐Containing Hydroxamic Acids as Selective HDAC6 Inhibitors

inferred← citeshttps://doi.org/10.1002/cmdc.200900082openalex-snapshot

Pyrrole‐Based Hydroxamates and 2‐Aminoanilides: Histone Deacetylase Inhibition and Cellular Activities

inferred← citeshttps://doi.org/10.1002/cmdc.201100007openalex-snapshot

Carbamate Prodrug Concept for Hydroxamate HDAC Inhibitors

inferred← citeshttps://doi.org/10.1002/ddr.20275openalex-snapshot

Newly developed effective anti‐cancer drugs targeting multiple myeloma

inferred← citeshttps://doi.org/10.1002/glia.22624openalex-snapshot

HDAC6 inhibition results in tau acetylation and modulates tau phosphorylation and degradation in oligodendrocytes

inferred← citeshttps://doi.org/10.1002/ijc.28924openalex-snapshot

Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6-independent ER stress-induced mechanism

inferred← citeshttps://doi.org/10.1002/jcb.22185openalex-snapshot

Histone deacetylase inhibitors: Potential in cancer therapy

inferred← citeshttps://doi.org/10.1002/med.20169openalex-snapshot

Strategies in developing promising histone deacetylase inhibitors

inferred← citeshttps://doi.org/10.1002/med.20178openalex-snapshot

NAD+-dependent histone deacetylases (sirtuins) as novel therapeutic targets

inferred← citeshttps://doi.org/10.1002/med.21972openalex-snapshot

Histone deacetylase‐based dual targeted inhibition in multiple myeloma

inferred← citeshttps://doi.org/10.1002/mnfr.201000547openalex-snapshot

Differential effects of sulforaphane on histone deacetylases, cell cycle arrest and apoptosis in normal prostate cells versus hyperplastic and cancerous prostate cells

inferred← citeshttps://doi.org/10.1002/pbc.24271openalex-snapshot

A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: A Children's Oncology Group phase I consortium study (ADVL0916)

inferred← citeshttps://doi.org/10.1002/pmic.201200233openalex-snapshot

Quantitative proteomic analysis to decipher the differential apoptotic response of bortezomib‐treated APL cells before and after retinoic acid differentiation reveals involvement of protein toxicity mechanisms

inferred← citeshttps://doi.org/10.1002/slct.201601117openalex-snapshot

Engineering and In Vitro Evaluation of Acid Labile Cholesterol Tethered MG132 Nanoparticle for Targeting Ubiquitin‐Proteasome System in Cancer

inferred← citeshttps://doi.org/10.1007/978-1-4020-6554-5_12openalex-snapshot

Targeting Proteasomes as Therapy in Multiple Myeloma

inferred← citeshttps://doi.org/10.1007/978-1-4419-0717-2_10openalex-snapshot

Histone Deacetylases (HDAC)

inferred← citeshttps://doi.org/10.1007/978-1-4419-6706-0_4openalex-snapshot

Endoplasmic Reticulum Stress and BCL-2 Family Members

inferred← citeshttps://doi.org/10.1007/978-1-4614-0730-0openalex-snapshot

Cell Signaling & Molecular Targets in Cancer

inferred← citeshttps://doi.org/10.1007/978-1-4614-0730-0_5openalex-snapshot

Signalling Molecules as Selective Targets for Therapeutic Strategies in Multiple Myeloma

inferred← citeshttps://doi.org/10.1007/978-1-4614-3764-2_27openalex-snapshot

Cytokines and Signal Transduction in Multiple Myeloma

inferred← citeshttps://doi.org/10.1007/978-1-4614-4666-8_14openalex-snapshot

Epigenetic Regulation of Myeloma Within Its Bone Marrow Microenvironment

inferred← citeshttps://doi.org/10.1007/978-1-4614-5260-7_9openalex-snapshot

Novel Agents in Multiple Myeloma

inferred← citeshttps://doi.org/10.1007/978-1-4614-6613-0_10-3openalex-snapshot

Histone Deacetylases (HDAC)

inferred← citeshttps://doi.org/10.1007/978-1-59745-474-2_8openalex-snapshot

Histone Deacetylase Inhibitors and Anticancer Activity

inferred← citeshttps://doi.org/10.1007/978-1-59745-564-0_24openalex-snapshot

Histone Deacetylase Inhibitors in Multiple Myeloma

inferred← citeshttps://doi.org/10.1007/978-1-59745-564-0_26openalex-snapshot

Proteasome Inhibitors as Therapy in Multiple Myeloma

inferred← citeshttps://doi.org/10.1007/978-1-59745-564-0_3openalex-snapshot

Basic Biology of Plasma Cell Dyscrasias: Focus on the Role of the Tumor Microenviroment

inferred← citeshttps://doi.org/10.1007/978-1-60327-424-1_10openalex-snapshot

Targeted Therapy in Multiple Myeloma

inferred← citeshttps://doi.org/10.1007/978-1-60761-389-3_29openalex-snapshot

Clinical and Pathologic Issues in Patients with Amyloidosis: Practical Comments Regarding Diagnosis, Therapy, and Solid Organ Transplantation

inferred← citeshttps://doi.org/10.1007/978-3-030-73440-4_7openalex-snapshot

Histone Deacetylase Inhibitors

inferred← citeshttps://doi.org/10.1007/978-3-319-06752-0_1openalex-snapshot

Proteasome Inhibitors and Lessons Learned from Their Mechanisms of Action and Resistance in Human Cancer

inferred← citeshttps://doi.org/10.1007/978-3-319-06752-0_11openalex-snapshot

Proteotoxic Stress and Proteasome Inhibitor Efficacy and Resistance

inferred← citeshttps://doi.org/10.1007/978-3-319-06752-0_2openalex-snapshot

Resistance to Proteasome Inhibitors in Multiple Myeloma

inferred← citeshttps://doi.org/10.1007/978-3-319-06752-0_6openalex-snapshot

Targeting Mantle Cell Lymphoma with a Strategy of Combined Proteasome and Histone Deacetylase Inhibition

inferred← citeshttps://doi.org/10.1007/978-3-319-19294-9_36openalex-snapshot

Clinical and Pathologic Issues in Patients with Amyloidosis: Summary and Practical Comments Regarding Diagnosis, Therapy, and Solid Organ Transplantation

inferred← citeshttps://doi.org/10.1007/978-3-319-40320-5_2openalex-snapshot

Vision Statement for Multiple Myeloma: Future Directions

inferred← citeshttps://doi.org/10.1007/978-3-319-61872-2_5openalex-snapshot

Treatment of Patients in First or Second Relapse

inferred← citeshttps://doi.org/10.1007/978-3-319-75184-9_3openalex-snapshot

Proteasome Inhibitors with a Focus on Bortezomib

inferred← citeshttps://doi.org/10.1007/978-3-540-31209-3_10openalex-snapshot

Clinical Relevance of Targeted Interference with Src-Mediated Signal Transduction Events

inferred← citeshttps://doi.org/10.1007/978-3-540-34594-7_10openalex-snapshot

Histone Deacetylase Inhibitors in APL and Beyond

inferred← citeshttps://doi.org/10.1007/978-3-540-85772-3_8openalex-snapshot

Novel Drugs in Myeloma: Harnessing Tumour Biology to Treat Myeloma

inferred← citeshttps://doi.org/10.1007/978-3-642-01222-8_12openalex-snapshot

Bortezomib

inferred← citeshttps://doi.org/10.1007/978-3-642-38404-2_10openalex-snapshot

Histone Deacetylase (HDAC) Inhibitors in Recent Clinical Trials for Cancer Therapy

inferred← citeshttps://doi.org/10.1007/978-3-642-54490-3_20openalex-snapshot

Bortezomib

inferred← citeshttps://doi.org/10.1007/978-3-7643-8948-2_2openalex-snapshot

Preclinical Activities of Bortezomib in MM, the Bone Marrow Microenvironment and Pharmacogenomics

inferred← citeshttps://doi.org/10.1007/978-3-7643-8948-2_6openalex-snapshot

Bortezomib in Relapsed and Relapsed/Refractory Multiple Myeloma

inferred← citeshttps://doi.org/10.1007/978-3-7643-8989-5_9openalex-snapshot

HDAC Inhibitors and Cancer Therapy

inferred← citeshttps://doi.org/10.1007/978-94-007-0344-5_30openalex-snapshot

Aggravating Endoplasmic Reticulum Stress by Combined Application of Bortezomib and Celecoxib as a Novel Therapeutic Strategy for Glioblastoma

inferred← citeshttps://doi.org/10.1007/978-94-007-2923-0_3openalex-snapshot

Chemoprevention of Prostate Cancer with Cruciferous Vegetables: Role of Epigenetics

inferred← citeshttps://doi.org/10.1007/978-981-15-8179-3_10openalex-snapshot

Combining Histone Deacetylase Inhibitors with Other Anticancer Agents as a Novel Strategy for Circumventing Limited Therapeutic Efficacy and Mitigating Toxicity

inferred← citeshttps://doi.org/10.1007/978-981-96-0301-5_5openalex-snapshot

Relevance of Small Molecule Inhibitors in Advancing Cancer Therapeutics

inferred← citeshttps://doi.org/10.1007/s00018-018-2966-xopenalex-snapshot

Bardet–Biedl Syndrome proteins regulate cilia disassembly during tissue maturation

inferred← citeshttps://doi.org/10.1007/s00253-015-7107-yopenalex-snapshot

Eukaryotic aggresomes: from a model of conformational diseases to an emerging type of immobilized biocatalyzers

inferred← citeshttps://doi.org/10.1007/s00262-023-03624-yopenalex-snapshot

HDAC6 inhibitor ACY-1215 enhances STAT1 acetylation to block PD-L1 for colorectal cancer immunotherapy

inferred← citeshttps://doi.org/10.1007/s00277-006-0239-5openalex-snapshot

Towards a new age in the treatment of multiple myeloma

inferred← citeshttps://doi.org/10.1007/s00280-010-1324-yopenalex-snapshot

Identification of type-specific anticancer histone deacetylase inhibitors: road to success

inferred← citeshttps://doi.org/10.1007/s00280-020-04043-xopenalex-snapshot

Involvement of ER stress and reactive oxygen species generation in anti-cancer effect of CKD-516 for lung cancer

inferred← citeshttps://doi.org/10.1007/s00401-013-1158-xopenalex-snapshot

Inclusion body formation, macroautophagy, and the role of HDAC6 in neurodegeneration

inferred← citeshttps://doi.org/10.1007/s10495-017-1364-4openalex-snapshot

Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine

inferred← citeshttps://doi.org/10.1007/s10555-006-8500-xopenalex-snapshot

Molecular mechanisms of metastasis

inferred← citeshttps://doi.org/10.1007/s10555-017-9698-5openalex-snapshot

Emerging small molecule approaches to enhance the antimyeloma benefit of proteasome inhibitors

inferred← citeshttps://doi.org/10.1007/s10555-017-9699-4openalex-snapshot

(Immuno)proteasomes as therapeutic target in acute leukemia

inferred← citeshttps://doi.org/10.1007/s10555-017-9707-8openalex-snapshot

The proteasome and proteasome inhibitors in multiple myeloma

inferred← citeshttps://doi.org/10.1007/s10637-010-9589-xopenalex-snapshot

The DAC system and associations with multiple myeloma

inferred← citeshttps://doi.org/10.1007/s10637-010-9596-yopenalex-snapshot

Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect

inferred← citeshttps://doi.org/10.1007/s11095-010-0318-0openalex-snapshot

Inorganic Nanoparticles in Cancer Therapy

inferred← citeshttps://doi.org/10.1007/s11899-009-0014-5openalex-snapshot

Treatment of relapsed and refractory myeloma

inferred← citeshttps://doi.org/10.1007/s11899-013-0173-2openalex-snapshot

Management of Double-Refractory Multiple Myeloma

inferred← citeshttps://doi.org/10.1007/s11899-016-0312-7openalex-snapshot

Practical Approaches to the Management of Dual Refractory Multiple Myeloma

inferred← citeshttps://doi.org/10.1007/s12032-009-9376-8openalex-snapshot

Future directions in immunomodulatory therapy

inferred← citeshttps://doi.org/10.1007/s12035-017-0558-7openalex-snapshot

UCH-L1 Inhibition Suppresses tau Aggresome Formation during Proteasomal Impairment

inferred← citeshttps://doi.org/10.1007/s12185-011-0917-5openalex-snapshot

Novel therapies in MM: from the aspect of preclinical studies

inferred← citeshttps://doi.org/10.1007/s12185-013-1290-3openalex-snapshot

Histone deacetylase inhibitors in the treatment for multiple myeloma

inferred← citeshttps://doi.org/10.1007/s12185-016-2008-0openalex-snapshot

Histone deacetylase inhibitors in multiple myeloma: from bench to bedside

inferred← citeshttps://doi.org/10.1007/s12185-016-2040-0openalex-snapshot

Mechanisms of action and resistance for multiple myeloma novel drug treatments

inferred← citeshttps://doi.org/10.1007/s12253-011-9432-5openalex-snapshot

Down-Regulated Expression of HSP70 in Correlation with Clinicopathology of Cholangiocarcinoma

inferred← citeshttps://doi.org/10.1007/s12263-012-0283-9openalex-snapshot

Histone deacetylase modulators provided by Mother Nature

inferred← citeshttps://doi.org/10.1007/s13148-010-0012-4openalex-snapshot

Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy

inferred← citeshttps://doi.org/10.1007/s13402-022-00704-6openalex-snapshot

HDAC6: A unique HDAC family member as a cancer target

inferred← citeshttps://doi.org/10.1007/s40262-017-0565-xopenalex-snapshot

Clinical Pharmacokinetics and Pharmacodynamics of Panobinostat

inferred← citeshttps://doi.org/10.1016/b978-0-12-374145-5.00325-9openalex-snapshot

The Evolution and Maintenance of the Multiple Myeloma Cell Clone within the Liquid Bone Marrow Compartment

inferred← citeshttps://doi.org/10.1016/b978-0-12-394387-3.00004-5openalex-snapshot

HDAC Inhibitor Modulation of Proteotoxicity as a Therapeutic Approach in Cancer

inferred← citeshttps://doi.org/10.1016/b978-0-12-394387-3.00006-9openalex-snapshot

Histone Deacetylase Inhibitors and Rational Combination Therapies

inferred← citeshttps://doi.org/10.1016/b978-0-12-394387-3.00007-0openalex-snapshot

HDAC Inhibitors and Chaperone Function

inferred← citeshttps://doi.org/10.1016/b978-0-12-801944-3.00005-9openalex-snapshot

Targeting Selective Autophagy of Insoluble Protein Aggregates

inferred← citeshttps://doi.org/10.1016/b978-0-12-816435-8.00013-4openalex-snapshot

Proteasome Inhibitors as Sensitizing Agents for Cancer Chemotherapy

inferred← citeshttps://doi.org/10.1016/b978-0-323-47674-4.00101-8openalex-snapshot

Multiple Myeloma and Related Disorders

inferred← citeshttps://doi.org/10.1016/b978-0-323-69538-1.00029-xopenalex-snapshot

Myeloma and Leukemia

inferred← citeshttps://doi.org/10.1016/bs.acr.2015.03.002openalex-snapshot

Emerging Therapeutic Strategies for Overcoming Proteasome Inhibitor Resistance

inferred← citeshttps://doi.org/10.1016/j.addr.2008.03.013openalex-snapshot

Biological properties of “naked” metal nanoparticles☆

inferred← citeshttps://doi.org/10.1016/j.arr.2014.07.002openalex-snapshot

Clearance of misfolded and aggregated proteins by aggrephagy and implications for aggregation diseases

inferred← citeshttps://doi.org/10.1016/j.bbagrm.2010.10.002openalex-snapshot

Protein lysine acetylation in cellular function and its role in cancer manifestation

inferred← citeshttps://doi.org/10.1016/j.bbamcr.2010.06.001openalex-snapshot

Accumulation of polyubiquitylated proteins in response to Ala-Ala-Phe-chloromethylketone is independent of the inhibition of tripeptidyl peptidase II

inferred← citeshttps://doi.org/10.1016/j.bbcan.2022.188676openalex-snapshot

Histone deacetylases: A novel class of therapeutic targets for pancreatic cancer

inferred← citeshttps://doi.org/10.1016/j.bbrc.2006.07.185openalex-snapshot

Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells

inferred← citeshttps://doi.org/10.1016/j.bbrc.2008.03.019openalex-snapshot

Inhibition of histone deacetylase1 induces autophagy

inferred← citeshttps://doi.org/10.1016/j.bbrc.2009.08.009openalex-snapshot

The microtubule-targeting agent T0070907 induces proteasomal degradation of tubulin

inferred← citeshttps://doi.org/10.1016/j.bbrc.2016.09.128openalex-snapshot

Mechanism of paclitaxel resistance in a human prostate cancer cell line, PC3-PR, and its sensitization by cabazitaxel

inferred← citeshttps://doi.org/10.1016/j.bcp.2012.06.014openalex-snapshot

Development and therapeutic impact of HDAC6-selective inhibitors

inferred← citeshttps://doi.org/10.1016/j.beha.2007.09.008openalex-snapshot

From the bench to the bedside: emerging new treatments in multiple myeloma

inferred← citeshttps://doi.org/10.1016/j.beha.2012.04.007openalex-snapshot

Proteasome inhibitors in mantle cell lymphoma

inferred← citeshttps://doi.org/10.1016/j.bioactmat.2025.02.040openalex-snapshot

Organelle-oriented nanomedicines in tumor therapy: Targeting, escaping, or collaborating?

inferred← citeshttps://doi.org/10.1016/j.biomaterials.2010.04.007openalex-snapshot

The influence of mediators of intracellular trafficking on transgene expression efficacy of polymer–plasmid DNA complexes

inferred← citeshttps://doi.org/10.1016/j.biomaterials.2019.119604openalex-snapshot

DMSO impairs the transcriptional program for maternal-to-embryonic transition by altering histone acetylation

inferred← citeshttps://doi.org/10.1016/j.bioorg.2021.105278openalex-snapshot

Development of selective HDAC6 inhibitors with in vitro and in vivo anti-multiple myeloma activity

inferred← citeshttps://doi.org/10.1016/j.bioorg.2022.106217openalex-snapshot

CC1007, a small molecular compound, suppresses multiple myeloma via upregulation of Nur77

inferred← citeshttps://doi.org/10.1016/j.biopha.2020.110454openalex-snapshot

Molecular docking-based virtual drug screening revealing an oxofluorenyl benzamide and a bromonaphthalene sulfonamido hydroxybenzoic acid as HDAC6 inhibitors with cytotoxicity against leukemia cells

inferred← citeshttps://doi.org/10.1016/j.bmc.2007.10.092openalex-snapshot

Phenylalanine-containing hydroxamic acids as selective inhibitors of class IIb histone deacetylases (HDACs)

inferred← citeshttps://doi.org/10.1016/j.bmc.2013.06.009openalex-snapshot

Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2)

inferred← citeshttps://doi.org/10.1016/j.bmc.2026.118762openalex-snapshot

Non-covalent dual HDAC6/proteasome inhibitors with anti-multiple myeloma activity

inferred← citeshttps://doi.org/10.1016/j.bmcl.2006.12.117openalex-snapshot

Identification of a potent and stable antiproliferative agent by the prodrug formation of a thiolate histone deacetylase inhibitor

inferred← citeshttps://doi.org/10.1016/j.bmcl.2011.08.027openalex-snapshot

The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity

inferred← citeshttps://doi.org/10.1016/j.bmcl.2014.10.022openalex-snapshot

Histone deacetylase inhibitors derived from 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine and related heterocycles selective for the HDAC6 isoform

inferred← citeshttps://doi.org/10.1016/j.canlet.2008.03.037openalex-snapshot

Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy

inferred← citeshttps://doi.org/10.1016/j.canlet.2008.07.005openalex-snapshot

Endoplasmic reticulum stress and autophagy as targets for cancer therapy

inferred← citeshttps://doi.org/10.1016/j.canlet.2008.08.016openalex-snapshot

HDAC family: What are the cancer relevant targets?

inferred← citeshttps://doi.org/10.1016/j.canlet.2009.01.040openalex-snapshot

Histone deacetylase inhibitors that target tubulin

inferred← citeshttps://doi.org/10.1016/j.canlet.2009.02.013openalex-snapshot

Isoform-specific histone deacetylase inhibitors: The next step?

inferred← citeshttps://doi.org/10.1016/j.canlet.2009.02.019openalex-snapshot

Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges

inferred← citeshttps://doi.org/10.1016/j.canlet.2012.06.016openalex-snapshot

Molecular crosstalk between the proteasome, aggresomes and autophagy: Translational potential and clinical implications

inferred← citeshttps://doi.org/10.1016/j.canlet.2017.01.033openalex-snapshot

HDAC6 deacetylates p53 at lysines 381/382 and differentially coordinates p53-induced apoptosis

inferred← citeshttps://doi.org/10.1016/j.canlet.2019.02.003openalex-snapshot

Proteasome inhibitor b-AP15 induces enhanced proteotoxicity by inhibiting cytoprotective aggresome formation

inferred← citeshttps://doi.org/10.1016/j.ccr.2013.11.001openalex-snapshot

A bis-Benzylidine Piperidone Targeting Proteasome Ubiquitin Receptor RPN13/ADRM1 as a Therapy for Cancer

inferred← citeshttps://doi.org/10.1016/j.cell.2007.04.035openalex-snapshot

HEF1-Dependent Aurora A Activation Induces Disassembly of the Primary Cilium

inferred← citeshttps://doi.org/10.1016/j.chembiol.2022.12.007openalex-snapshot

Inhibitors of the ATPase p97/VCP: From basic research to clinical applications

inferred← citeshttps://doi.org/10.1016/j.clml.2013.03.016openalex-snapshot

Histone Deacetylase Inhibitors in Multiple Myeloma: Rationale and Evidence for Their Use in Combination Therapy

inferred← citeshttps://doi.org/10.1016/j.clml.2016.02.042openalex-snapshot

VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma

inferred← citeshttps://doi.org/10.1016/j.clml.2017.05.007openalex-snapshot

Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma

inferred← citeshttps://doi.org/10.1016/j.clml.2018.03.002openalex-snapshot

An Expanded Treatment Protocol of Panobinostat Plus Bortezomib and Dexamethasone in Patients With Previously Treated Myeloma

inferred← citeshttps://doi.org/10.1016/j.clml.2020.07.013openalex-snapshot

Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

inferred← citeshttps://doi.org/10.1016/j.clml.2020.11.019openalex-snapshot

Bortezomib, Vorinostat, and Dexamethasone Combination Therapy in Relapsed Myeloma: Results of the Phase 2 MUK four Trial

inferred← citeshttps://doi.org/10.1016/j.clml.2021.06.020openalex-snapshot

Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma

inferred← citeshttps://doi.org/10.1016/j.cmonc.2012.02.009openalex-snapshot

Bench-to-bedside translation of targeted therapies in multiple myeloma

inferred← citeshttps://doi.org/10.1016/j.coph.2006.03.010openalex-snapshot

Histone deacetylase inhibitors: gathering pace

inferred← citeshttps://doi.org/10.1016/j.ctrv.2011.04.001openalex-snapshot

Targeted therapies for advanced non-small-cell lung cancer: Current status and future implications

inferred← citeshttps://doi.org/10.1016/j.ctrv.2018.09.001openalex-snapshot

Drug resistance in multiple myeloma

inferred← citeshttps://doi.org/10.1016/j.drup.2008.08.002openalex-snapshot

Mechanisms of proteasome inhibitor action and resistance in cancer

inferred← citeshttps://doi.org/10.1016/j.drup.2010.04.003openalex-snapshot

Macroautophagy modulates cellular response to proteasome inhibitors in cancer therapy

inferred← citeshttps://doi.org/10.1016/j.drup.2014.12.001openalex-snapshot

Molecular basis of resistance to proteasome inhibitors in hematological malignancies

inferred← citeshttps://doi.org/10.1016/j.ejmech.2021.113874openalex-snapshot

Inhibition of Histone Deacetylase 6 (HDAC6) as a therapeutic strategy for Alzheimer's disease: A review (2010–2020)

inferred← citeshttps://doi.org/10.1016/j.ejmech.2024.116435openalex-snapshot

Research strategies of small molecules as chemotherapeutics to overcome multiple myeloma resistance

inferred← citeshttps://doi.org/10.1016/j.ejmech.2024.117208openalex-snapshot

Synthesis and functional screening of novel inhibitors targeting the HDAC6 zinc finger ubiquitin-binding domain

inferred← citeshttps://doi.org/10.1016/j.ejphar.2025.178303openalex-snapshot

Doxorubicin-mediated retardation of aggresome formation enhances Carfilzomib-induced cell death synergistically by augmenting ER stress and proapoptotic signaling

inferred← citeshttps://doi.org/10.1016/j.ejphar.2026.178721openalex-snapshot

Bridging protein quality control and epigenetic dysregulation: The HDAC6 paradox in neurological disorders and therapeutic targeting

inferred← citeshttps://doi.org/10.1016/j.exphem.2007.01.024openalex-snapshot

Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions

inferred← citeshttps://doi.org/10.1016/j.exphem.2015.04.010openalex-snapshot

Novel therapeutic strategies for multiple myeloma

inferred← citeshttps://doi.org/10.1016/j.freeradbiomed.2012.09.023openalex-snapshot

Histone deacetylase 6 (HDAC6) plays a crucial role in p38MAPK-dependent induction of heme oxygenase-1 (HO-1) in response to proteasome inhibition

inferred← citeshttps://doi.org/10.1016/j.hoc.2007.08.013openalex-snapshot

Preclinical Studies of Novel Targeted Therapies

inferred← citeshttps://doi.org/10.1016/j.hoc.2010.08.013openalex-snapshot

Protein Quality Control During Erythropoiesis and Hemoglobin Synthesis

inferred← citeshttps://doi.org/10.1016/j.hoc.2012.01.006openalex-snapshot

Role of Histone Deacetylase Inhibitors in the Treatment of Lymphomas and Multiple Myeloma

inferred← citeshttps://doi.org/10.1016/j.hoc.2014.07.001openalex-snapshot

Novel Targeted Agents in the Treatment of Multiple Myeloma

inferred← citeshttps://doi.org/10.1016/j.hoc.2016.11.002openalex-snapshot

Novel Agents in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma

inferred← citeshttps://doi.org/10.1016/j.hoc.2023.12.016openalex-snapshot

Proteasome Inhibitors in Multiple Myeloma

inferred← citeshttps://doi.org/10.1016/j.jns.2011.02.017openalex-snapshot

HDAC6 α-tubulin deacetylase: A potential therapeutic target in neurodegenerative diseases

inferred← citeshttps://doi.org/10.1016/j.jprot.2019.01.009openalex-snapshot

A large scale proteome analysis of the gefitinib primary resistance overcome by KDAC inhibition in KRAS mutated adenocarcinoma cells overexpressing amphiregulin

inferred← citeshttps://doi.org/10.1016/j.jss.2013.03.052openalex-snapshot

Synergistic inhibition of thyroid cancer by suppressing MAPK/PI3K/AKT pathways

inferred← citeshttps://doi.org/10.1016/j.kint.2016.01.026openalex-snapshot

Inhibition of histone deacetylase 6 activity reduces cyst growth in polycystic kidney disease

inferred← citeshttps://doi.org/10.1016/j.leukres.2010.04.001openalex-snapshot

Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma

inferred← citeshttps://doi.org/10.1016/j.leukres.2012.02.026openalex-snapshot

HDAC6 as a target for antileukemic drugs in acute myeloid leukemia

inferred← citeshttps://doi.org/10.1016/j.leukres.2012.02.029openalex-snapshot

Bortezomib and panobinostat combination is effective against PTCL

inferred← citeshttps://doi.org/10.1016/j.leukres.2013.03.006openalex-snapshot

Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma

inferred← citeshttps://doi.org/10.1016/j.leukres.2020.106398openalex-snapshot

A452, HDAC6-selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in IMiDs-resistant multiple myeloma

inferred← citeshttps://doi.org/10.1016/j.lfs.2025.123749openalex-snapshot

PSME2 promotes malignant progression through autophagy modulation via IL-6/STAT3 signaling pathway in esophageal squamous cell carcinoma

inferred← citeshttps://doi.org/10.1016/j.mayocp.2015.11.007openalex-snapshot

Multiple Myeloma: Diagnosis and Treatment

inferred← citeshttps://doi.org/10.1016/j.mayocp.2017.01.003openalex-snapshot

Therapy for Relapsed Multiple Myeloma

inferred← citeshttps://doi.org/10.1016/j.niox.2007.01.001openalex-snapshot

Hydroxyurea increases eNOS protein levels through inhibition of proteasome activity

inferred← citeshttps://doi.org/10.1016/j.pharmthera.2014.04.004openalex-snapshot

Histone deacetylase inhibitor (HDACI) mechanisms of action: Emerging insights

inferred← citeshttps://doi.org/10.1016/j.phrs.2015.08.002openalex-snapshot

Transcriptional dysregulation in Huntington’s disease: The role of histone deacetylases

inferred← citeshttps://doi.org/10.1016/j.phrs.2017.11.004openalex-snapshot

Anti-cancer effects of naturally derived compounds targeting histone deacetylase 6-related pathways

inferred← citeshttps://doi.org/10.1016/j.pneurobio.2017.08.005openalex-snapshot

Progressing neurobiological strategies against proteostasis failure: Challenges in neurodegeneration

inferred← citeshttps://doi.org/10.1016/j.treopn.2026.08.003openalex-snapshot

Nondegradative ubiquitination organizes therapy-relevant stress assemblies

inferred← citeshttps://doi.org/10.1016/j.virol.2008.02.034openalex-snapshot

Susceptibility to virus–cell fusion at the plasma membrane is reduced through expression of HIV gp41 cytoplasmic domains

inferred← citeshttps://doi.org/10.1016/j.virusres.2012.12.006openalex-snapshot

African swine fever virus-cell interactions: From virus entry to cell survival

inferred← citeshttps://doi.org/10.1016/j.ymgme.2008.03.012openalex-snapshot

The aggresome pathway as a target for therapy in hematologic malignancies

inferred← citeshttps://doi.org/10.1016/s0140-6736(09)60221-xopenalex-snapshot

Multiple myeloma

inferred← citeshttps://doi.org/10.1016/s1016-8478(23)14003-9openalex-snapshot

Proteotoxic Stress and Cell Lifespan Control

inferred← citeshttps://doi.org/10.1016/s1470-2045(08)70304-8openalex-snapshot

New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings

inferred← citeshttps://doi.org/10.1016/s1470-2045(11)70327-8openalex-snapshot

Histone deacetylase inhibitors and Hodgkin's lymphoma

inferred← citeshttps://doi.org/10.1016/s1470-2045(13)70398-xopenalex-snapshot

Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study

inferred← citeshttps://doi.org/10.1016/s1470-2045(14)70443-7openalex-snapshot

Panobinostat for the treatment of multiple myeloma

inferred← citeshttps://doi.org/10.1016/s1470-2045(16)30375-8openalex-snapshot

Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial

inferred← citeshttps://doi.org/10.1016/s2352-3026(15)00097-6openalex-snapshot

Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial

inferred← citeshttps://doi.org/10.1016/s2352-3026(15)00116-7openalex-snapshot

Combination therapy for relapsed peripheral T-cell lymphoma: is two better than one?

inferred← citeshttps://doi.org/10.1016/s2352-3026(16)30165-xopenalex-snapshot

Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial

inferred← citeshttps://doi.org/10.1017/cbo9780511551901.005openalex-snapshot

TREATMENT OF RELAPSED AND RELAPSED/REFRACTORY MULTIPLE MYELOMA

inferred← citeshttps://doi.org/10.1017/cbo9780511862465.009openalex-snapshot

Principles of pathway directed therapy

showing the first 200 of 570 · page through all 570

Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.